ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]

Read more

ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer

Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simmen PhD and Alison Humbles PhD as Strategic Advisors. Dr Simmen and Dr Humbles bring decades of experience gained in big pharma, specifically […]

Read more

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]

Read more

ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults

Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]

Read more

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]

Read more

ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research

Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]

Read more

ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults

New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]

Read more

ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051

When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]

Read more

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities Melbourne, Australia, 5 September 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections […]

Read more

ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051

Advances a new formulation with improved stability in the clinic Single ascending dose phase successfully completed, multiple ascending dose phase underway Melbourne, Australia, 27 August 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has […]

Read more